Overactive bladder is a condition in which a person gets sudden urge to pass urine. In addition, bladder contracts giving little time or no time to reach to the toilet. This condition is also known as urge incontinence. Increasing aging population, increase in diabetic population, continuous rise in prevalence of overactive bladder condition, increasing consumption of alcohol and caffeinated drinks and neurological conditions such as multiple sclerosis and Parkinson’s are contributing significantly to the growth of the market. As per Urology Care Foundation, around 33 million Americans have overactive bladder, in which 30% of men and 40% of women live with OAB symptoms. In addition, National Overactive Bladder Evaluation (NOBLE) program conducted a telephone survey and found that 16.9% of women had OAB, 9.3% with urge incontinence and 7.6% without urge incontinence. It also revealed that 16% of men had OAB in Canada.
Increasing activity of key players to provide advanced therepies for the diagnosis and treatment of overactive bladder. For instance, Botox bladder injection provided by Allergan is a novel therapy. It is effective in cases of urinary urgency incontinence.
Global overactive bladder treatment market accounted for over USD 4.1 billion in 2017 and is expected to grow at a CAGR of 4.5 % during the forecast period, 2019–2026.
To learn more about key trends >> Download Sample Report
Global overactive bladder treatment market is segmented by pharmacotherapy and disease type.
By pharmacotherapy, the market is segmented into anticholinergic, mirabegron, botox and neurostimulation. Anticholinergics are expected to grow at the fastest CAGR. The growth can be attributed to being the first line of medication for the treatment of indication. Anticholinergics is sub segmented into solifenacin, oxybutynin, fesoterodine, darifenacin, tolterodine, trospium and other anticholinergics.
By disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. Neurogenic overactive bladder is further segmented into overactive bladder in Parkinson’s disease, overactive bladder in stroke, overactive bladder in multiple sclerosis, overactive bladder in spinal cord injury and overactive bladder in other disorders. The idiopathic overactive bladder treatment segment is projected to hold the largest share as the condition is high in prevalence and affects women more due to weak bladder muscles post pregnancy and menopause.
Geographically, the global overactive bladder treatment market is segmented into four regions: North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
To understand geography trends >> Download Sample Report
North America is expected to have control over the overactive bladder treatment market owing to its well-established healthcare industry, convenient compensation policy and a growing prevalence of the condition. As per American Urological Association, Bladder cancer holds for 16,000 American deaths each year. Moreover, Bladder cancer has the highest cost of health care compared to all other malignancies.
Europe is likely to emerge as the second largest overactive bladder market globally. This can be attributed to the increase in number of diabetic population in the region. As per International Diabetes Federation, in 2017, around 66 million people were diagnosed with diabetes and this number is expected to reach 81 million by 2045.
Asia Pacific overactive bladder market is expected to witness significant growth on account of increase in the number of geriatric population and rise in awareness among people regarding the condtion. As per The Journal of Obstetrics and Gynecology of India, around 1 in 3 women over 75 years of age and 1 in 15 women over 40 years suffer from the symptoms of an overactive bladder.
LAMEA is expected to witness steady growth in the market. Lack of awareness about these conditions and poor health infrastructure are major factors for the stagnant growth in the region. The regional burden of these conditions is estimated to be greatest in Africa (30.1–31.1%) increase and South America (20.5–24.7%) during 2008–2018.
Some of the key players in the global overactive bladder treatment market are Teva Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Astellas Pharma Inc, Pfizer, Inc., Mylan N.V., Allergan, PLC, Endo International PLC, Cogentix Medical, Inc, Endo International PLC, and Sanofi.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Pharmacotherapy (BOTOX, Neurostimulation), Disease Type, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Teva Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Astellas Pharma Inc, Pfizer, Inc., Mylan N.V., Allergan, PLC, Endo International PLC, Cogentix Medical, Inc, Endo International PLC, and Sanofi. ,|
|Key Market Opportunities||High Demand In Healthcare It Sector Is Pushing Overactive Bladder Treatment Market|